In conclusion, the results of this study suggest (i) that NOX2-derived ROS may contribute to leukemic expansion in mice carrying hematopoietic cells with mutated Kras and (ii) that strategies to target NOX2 merit further evaluation in RAS-mutated leukemia. This evidence concerns the gene KRAS and leukemia.